BLAIV (INFUSION)INJECTABLEPriority Review
Approved
Dec 2005
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
126
Data completeness
6/8 — Strong
Priority Review
ORENCIA (abatacept) by Bristol Myers Squibb is selective t cell costimulation modulator [epc]. Approved for rheumatoid arthritis, juvenile idiopathic arthritis. First approved in 2005.
ORENCIA (abatacept) is a selective T cell costimulation modulator approved as an intravenous infusion for the treatment of rheumatoid arthritis and other autoimmune conditions. As a fusion protein biologic, it works by modulating T cell activation, a key driver of immune-mediated inflammation. The drug represents an important class of immunosuppressive therapy that has established a significant role in treating moderate-to-severe rheumatoid arthritis, particularly in patients with inadequate response to conventional DMARDs.
$0.1BPart D
Mechanism of Action
Selective T Cell Costimulation Modulator
Indications (2)
Clinical Trials (126)
Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
Started May 2024
41 enrolled
Graft Vs Host DiseaseGraft-versus-host-diseaseGraft Versus Host Disease
Safety and Efficacy of Abatacept for Treating Chronic Cytopenia in Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) Haploinsufficiency
Started Nov 2023
0CTLA4 HaploinsufficencyChronic Cytopenia
Comparative Pharmacokinetic Study of Three Abatacept Products in Male Normal Healthy Volunteers by the Subcutaneous Route
Started Oct 2023
330 enrolled
Rheumatoid Arthritis
A Study to Evaluate the Drug Levels of Abatacept Converted From Drug Substance by Two Different Processes in Healthy Participants
Started Aug 2023
174 enrolled
Healthy Participants
Subcutaneous Abatacept in Renal Transplant Recipients
Started Aug 2023
16 enrolled
Kidney Transplant Recipient
Worked on ORENCIA at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.